Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study.

Blood Adv · 2023 · PMC10368773 · PMID 37163358

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Key Points • The final analysis of CANDOR confirmed a PFS benefit and showed a trend in OS favoring KdD vs Kd. • Results reinforce KdD as a standard of care for RRMM, especially in clinically relevant patient subgroups.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.